Treating peripheral neuropathy in individuals with type 2 diabetes mellitus with intraneural facilitation: a single blind randomized control trial. Issue 8 (August 2022)

• Record Type: Journal Article
• Authors: Sahba, Kyan; Berk, Lee; Bussell, Mark; Lohman, Everett; Zamora, Francis; Gharibvand, Lida
• Is Part Of: Journal of international medical research. Volume 50:Issue 8(2022)
• Publication Date: 2022-08
• Subjects: Diabetes -- neuropathy -- intraneural facilitation -- physiotherapy; Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/03000605221109390
• Languages: English
• ISSNs: 0300-0605

Abstract

Objective: To evaluate the effectiveness of intraneural facilitation (INF) for the treatment of diabetic peripheral neuropathy (DPN). Methods: This single-blind, randomized clinical trial enrolled patients with type 2 diabetes mellitus and moderate-to-severe DPN symptoms below the ankle. Patients were randomly assigned to receive INF or sham treatment. In the INF group, trained INF physical therapists provided therapy for 50–60 min, three times a week for 3 weeks. Sham treatment consisted of patients believing they received anodyne therapy for 3 weeks. Pre- and post-treatment data were compared between the two groups for quality of life, balance, gait, protective sensory function and pain outcome measures. Results: A total of 28 patients (17 males) were enrolled in the study (INF group n = 17; sham group n = 11). There was a significant decrease in the overall pain score in both the INF and sham groups over time, but the decrease was greater in the INF group (1.11 versus 0.82). Between-group comparisons demonstrated significant differences in unpleasant pain and protective sensory function. The INF group showed post-treatment improvements in protective sensory function and composite static balance score. Conclusions: INF treatment improved pain perception, the composite static balance score and protective sensations in patients with DPN. Research Registry number: CNCT04025320